for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ASKA Pharmaceutical Co., Ltd.

4514.T

Latest Trade

1,139.00JPY

Change

17.00(+1.52%)

Volume

77,000

Today's Range

1,105.00

 - 

1,144.00

52 Week Range

983.00

 - 

1,642.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,122.00
Open
1,123.00
Volume
77,000
3M AVG Volume
1.12
Today's High
1,144.00
Today's Low
1,105.00
52 Week High
1,642.00
52 Week Low
983.00
Shares Out (MIL)
28.26
Market Cap (MIL)
34,291.91
Forward P/E
21.13
Dividend (Yield %)
1.25

Next Event

Dividend For 4514.T - 7.0000 JPY

Latest Developments

More

ASKA Pharmaceutical says voluntary recall of hypertension treatment drug valsartan

Takeda Pharmaceutical and ASKA Pharmaceutical enter into licensing agreement for relugolix in women's health indications

ASKA Pharmaceutical to set up pharmaceutical JV in India

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ASKA Pharmaceutical Co., Ltd.

ASKA Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company. The Company operates in two business segments. The Pharmaceutical Products segment is engaged in the manufacture, purchase and sale of drugs. The Others segment is involved in the provision of clinical examination and test services, the sale of medical equipment, as well as the sale of food products. As of March 31, 2014, the Company had three subsidiaries and three associated companies.

Industry

Biotechnology & Drugs

Contact Info

2-5-1, Shibaura

+81.3.54848361

http://www.aska-pharma.co.jp

Executive Leadership

Takashi Yamaguchi

President, Representative Director

Atsushi Maruo

Senior Managing Director

Kazuhiko Kato

Managing Director

Yuichiro Fukui

Managing Executive Officer, President of Subsidiary, Director

Ikuo Kumano

Managing Executive Officer, Chief Director of Administration, Director

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (JPY)

2017

105.390

2018

84.800

2019

61.810

2020(E)

53.100
Price To Earnings (TTM)
25.45
Price To Sales (TTM)
0.72
Price To Book (MRQ)
0.75
Price To Cash Flow (TTM)
9.12
Total Debt To Equity (MRQ)
48.35
LT Debt To Equity (MRQ)
31.01
Return on Investment (TTM)
2.02
Return on Equity (TTM)
1.56

Latest News

BRIEF-ASKA Pharmaceutical to set up pharmaceutical JV in India

* Says it will set up a pharmaceutical JV with Omnicare Drugs India Private Limited, in India, in May

BRIEF-ASKA Pharmaceutical signs option agreement with Pieris Pharmaceuticals on anemia treatment drug PRS-080

* Says the company enters into an exclusive option agreement with Pieris Pharmaceuticals on development and sale of anemia treatment drug PRS-080 in Japan, Korea and other Asian countries

BRIEF-Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska pharmaceutical

* Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska Pharmaceutical

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up